DOCSLIB.ORG

Myelogram-Medications-To-Avoid.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Myelogram-Medications-To-Avoid.Pdf Medication to be held 48 Banaflex /skeletal muscle relaxer Clozaril/antischizophenia HOURS BEFORE AND 24 HOURS Bancap/contains caffei Cogentin/antidyskinectic/ant AFTER MYELOGRAM Banzel/seizure adjunct iemetic/antipsychotic Updated December 2016 BC powder/ contains caffeine Compazine/phenothiazine Belviq/appetite suppressant Concerta/CNS stimulant Abilify / antipsychotic Bevespi contains formoterol Contrave/antidepressant Acetophenazine/ antipsychotic Benzphetamine/appetite Cyclizine/ antiemetic Adderall/amphetamine and suppressant antivertigo agent dextroamphetamine Bismuth subcitrate potassium/ Cyclobenzaprine/muscle Adipex-P/stimulant/ anorectic mineral relaxer Adsuva/antidepressant Bonine/meclicine Cylert/ADHD agent Adphen/ /antidepressant Bontril/appetite suppressant Cymbalta/antidepressant/tri appetite suppressant Bontril PDM/appetite suppressant cyclic Adipost/ appetite suppressants, Bortezomib/antineoplastics Sympathomimetic (Systemic Brintxelli / antidepressant Adrafinil/cognitive enhancer Bucladin-S softab/antiemetic Dapex/appetite suppressant Alatrofloxacin/ antibacterial antivertigo Dayquil/contains caffeine Aliskiren Bucet/contains caffeine Darvon 65/contain caffeine Hemifumarate/antihypertensive Buclizine/antiemetic/antivertigo Daytrana/CNS stimulant direct renal inhibitor / Budeption/antidepressant Desipramine/tricyclic/antide Alsuma/s Buphenamine/appetite suppressant pressant Amaphen/ barbituate Buproban/antidepressantr Desoxyn/amphetamine Amitriptyline/ tricyclic BupropionBuffets/caffeine Desvenlafaxine succinate/ antidepressant Butalbital with Caffeine/caffeine antidepressant Amoxapine/antidepressants, Butace/contains caffeine Desyrel/antidepressant/antin tricyclic euragic Amphetamine/ stimulant Dexedrin/appetite Amrix/ muscle relaxer Cafatine/contains caffeine suppressant Anafranil/ antidepressants, Cafcit /contains caffeine Dexedrine/appetite tricyclic Cafergot/Contains caffeine suppressant Anergan 50/ phenothiazine- Cafetrate/ caffeine Dexmethyl derivative Caffeine I.V. or Phenidate/ADHD Agent Anoquan/ analgesic/ barbituate Caffeine Tablets or medicines Dextroamphetamine/appet Anoxine AM/ phentermine containing caffeine ite suppressant Antiflex/muscle relaxer Carbex/antiparkinson adjunct Dextrostat/amphetermine Antivert/ antiemetic/ antivertigo Cariprazine/antipsychotic DHC plus/contains caffeine Antizol/ antifreeze antidote Carisoprodol/muscle relaxer Didrex/appetite suppressant Antrizine/ antihistamine Cefepime/cephlosporin Diethylpropion/appetite Aplenzinantidepressant Celexa/SSRI suppressant Apo-Amitriptyline/Amitriptyline Cerebyx/anticonvulsant Dihydrocodonecaffeine / tricyclic antidepressant Certolizumab/ antibody for Dital/ appetite suppressant Arcet/contains caffeine Crohn’s Dizac/benzodiazepine Aricept / dementia symptoms Chlordiazepoxide/Amitriptyline/ Dizmiss/antiemetic/antiverti treatment adjunct tricycle /antidepressant go agent Aripiprazole/ antipsychotic Chlorpromazine/phenothiazine Dolmar/contains caffeine Aristada/ antipsyschotic inj. Chlorprothixene/antipsychotic/t Donepezil/Alzheiner adjunct Armodafinil/cognitive enhancer hioxanthenes Dopram/CNS depressant Artane/antidyskinectic/ Chlorzoxazone/muscle relaxer Doribax/gram(-) antibiotic antiemetic/antipsychotic Cidofovir/antiviral Doripenem/antibiotic Asenapine/ antipsychotic Cimzia/antibody for crohn’s Dothiepin/antidepressant Asendin/ tricyclic antidepressants Citalopram/antidepressant/tricyclic Doxapram/CNS depressant Atomoxetine/ selective Clomipramine/tricyclic/antidepress Doxepin/tricyclic/ Atarax phenothiazine ant antidepressant norepinephrine reuptake inhibitor Clorazepate/CNS depressant Dramamine/antiemetic/ Aventyl /tricyclic antidepressant Clorazpine/antipsychotic antivertigo Clozapine/antipschotic Droperidol/antinausea Page 1 of 4 PE14008 Addendum Droperidol with Fentanyl Furazolidoneantibacterial/ Meni- /antinausea antiprotozoan D/antiemetic/antivertigo Duloxetine/antidepressant Furoxone(same as furazolidone) Mepergan/contains Dyrexan/appetite suppressant Gelprin/contains caffeine phenothiazine Gen-Xene/antianxiety Mircera/protein for anemia Geodon/antipsychotic Meridia/appetite suppressant Effexor/antidepressant/anti Goody powder/ contains caffeine Meropenem/antibacterial anxiety agent Guanfacine/ADHD adjunct Merrem/antibacterial Elavil/tricyclic/ antidepressant Haldol/antidyskinectic/ Mesoridazine/ahenothiazine Endep/tricyclic/antidepressant antiemetic/antipsychotic Metadate CD/CNS stimulant Eldepryl/antiparkansonian adjunct Haloperidol(same as Haldol) Metaxalone/muscle relaxer Endolor/contains caffeine Hydroxyzine phenothiazine Methamphetamine/amphert /contains caffeine Iloperidone /antipsychotic amine Entacapone/antiparkansonian Imipramine/tricyclix/antidepressant Methotrimeprazine/antipsy adjunct Inapsine/antinauseous chotic Ercaf/contains caffeine Innovarantiemetic Methoxy Polyethy glycol- Escitalopramantidepressant Intuniv/ADHD adjunct epooetin beta Esgic/contains caffeine Invega/antipsycotic Methylin/CNS stimlant EsgicPlus/contains caffeine Ionamin/phenertermine MethylphenidateCNS Ethopropazineantidyskinectic Iproniazid/MAO antidepressant stimulant /antiparkinson adjunct Isocarboxazid/MAO antidepressant Methylphenidate extended Etrafon/tricyclic antidepressant Kapvay/ADHD adjunct releaseCNS Stimulant Etrafon 25/50/ tricyclic/ Lacosamide/seizure Milnacipran/Antidepressant antidepressant adjunct/anticonvulsant MioRel/muscle relaxer Etrafon A/tricyclic/antidepressant Largactil/phenothiazine Mirtazapine/antidepressant Extrafon Forte/ tricyclic/ Largon/antidepressant Moban/antischzophrenia antidepressant Latuda/antipsydhotic agent Excedrin/contains caffeine Levomilnnacipran antidepressant Modafinil/cognitive enhancer Exelon/dementia adjunct Levoprome/antipsychotic Modecate/phenothiazine Ezol/contains caffeine Levothyroxine Sodium Moditen/phenothiazine Fanapt/antipsychotic\ Levoxyl Molindone/antischzophrenia Fanapta/antipsychotic Lexapro/antidepressant agent Fastin/phenothiazine Levate/antidepressant Mus-Lax/muscle relaxer Femcet/contains caffeine Limbitrol/antianxiety/antipsychotic Myolin/muscle relaxer Fentanyl/ Droperidol Liquadd/CNS stimulant Myotrol/muscle relaxer Combination/ antiemetic Lisdexamfetamine Dimesylate/ Ferndex/amphetamine Amphetamine Fetzima antidepressant Lorzone muscle relaxer Namenda Fioricet/contains caffeine Loxapine/antipsychotic Nardil/ antidpressant Florinal/contains caffeine Loxipac/antidepressant Navane/thiothixene Flexeril/muscle relaxer Loxitane antianxiety/antidepressant schizophrenia agent Flexoject/muscle relaxer Ludiomil/antidepressant Nefazodone/antidepressant Fluoxetine/tricyclic antidepressant Lurasidone/antipsychotic Nilotinib Hydrochloride Flupenthixol/thioxanthene Luvox/SSRI Monohydrate/ Fluphenazineantipsychotic/ Maprotiline/tricyclic/antidepressant chemotherapy antischizophrenia Marezine/antiemetic/antivertigo No Doz/contains caffeine adjunct/phenothiazine Marplan/ADHDadjunct Norflexmuscle relaxer Fluvoxamine/antidepressant Maxipime/cephalosporin Norfraniltricyclic/antidepress Focalin/CNS depressant Mazanor/appetite suppressant ant (FocalinXR) Mazindol/appetite suppressant Norgesic / muscle relaxer Fomepizole/antifreeze poisoning Meclizine/antiemetic/antivertigo Norgesic Forte/analgesic antidote Medigesic/contains caffeine /muscle relaxer Forfivo XL/antidepressant Melfiat/appetite suppressant Norpramintricyclic/antidepre Formoterol Mellaril/tricyclic/antidepressant ssant Fumaarate/Inhalant Menantine/anti alzheimers Nortriptylinetricyclic t agent/dementia adjunct /antidepressant Page 2 of 4 PE14008 Addendum Novoperidol/antidepressant Pimozide/appetite suppressant Sedapac/contains caffeine Nuvigil/ cognitive enhancer Plegine/appetite suppressan Selegiline/antidyskinectic Nyquil Prelu-2appetite Suppressant Serentil/phenothiazine Pristiq/antidepressant Serqouel/antipsychotic Procentra/CNS stimlant Sertraline/antidepressant Obe-Nix 30 Obenix/appetite Prochlorperazine/phenothiazine Serzone/antidepressant suppressant Profluphenazine/antidepressant Shogan/phenothiazine Obephen/phenermine Prolixin/phenothiazine Sibutramine/appetite Obermine/phenermine Promazine/phenothiazine suppressant Obestin/phenermine Promethazinephenothiazine Silenor/(doxepin)tricyclic Olanzapine antischizophrenia Promethazine and Sinequan/tricyclic agent Combinationssame as above antidepressant Oleptro/antidepressant Propiomazinetricyclic Amitriptyline/antipsycholic Ondansetronantinauseous antidepressant SK-Pramine/appetite Onzetra Xsail/ sumatriptan nasal Propoxyphene Cpd-65 Caffeine suppressant powder Prothiadentricyclic antidepressant Skelaxin/muscle relaxer Orap/ /antipsychotic Protriptyline/tricyclic Soma/muscle relaxer Orflo/muscle relaxer antidepressant Soneta Ormazine/phenothiazine Provigil/cognitive enhancer Spancap/appetite Orphenadrine/muscle relaxer Prozac/antipsychoticantiobsessive suppressant Orphenate/muscle relaxer Prozine-50/neuroleptic Sparfloxacin/antibacterial Oxilapine/antidepressant Pylera/ antibody for crohn’s Sparine/antipsychotic Oxydess II/appetite suppressant Stelazine/phenothiazine Strattera/ADHD adjunct Quetiapine/antipsychotic Sumavel/SSRI Paliperidone/antipsychotic QuillivantantXR/ADHD adjunct Sunitdinib malate Pamelor/tricyclic/ antidepressant Qsymia/Phentermine HCL Supac/contains caffeine Paraflex Suprenza/appetite skeletal muscle relaxer suppressant Parafon Forte/skeletal muscle Racemic amphetamine Surmontil/tricyclic relaxer sulfateamphetermine antidepressant Parmine/appetite suppressant Rapiflux tricyclic antidepressant Sutent Parnate/antidepressant Recharge/contains caffeine
Load more

Recommended publications
  • Original Research Published, Reproduced, Transmitted, Modified, Posted, Sold, Licensed, Or Used for Commercial Purposes
    This work may not be copied, distributed, displayed, Original Research published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the Efficacy and Effectiveness of Depot publisher’s Terms & Conditions. Versus Oral Antipsychotics in Schizophrenia: Synthesizing Results Across Different Research Designs Noam Y. Kirson, PhD; Peter J. Weiden, MD; Sander Yermakov, MS; Wayne Huang, MPP; Thomas Samuelson, BA; Steve J. Offord, PhD; Paul E. Greenberg, MS, MA; and Bruce J. O. Wong, MD ABSTRACT he cornerstone of long-term maintenance therapy Objective: Nonadherence is a major challenge in schizophrenia Tof schizophrenia patients is relapse prevention. treatment. While long-acting (depot) antipsychotic medications are Relapse prevention is necessary—albeit not sufficient— often recommended to address adherence problems, evidence on for eventual successful rehabilitation.1 In practice, the the comparative effectiveness of depot versus oral antipsychotics is effectiveness of maintenance antipsychotic treatment is inconsistent. We hypothesize that this inconsistency could be due to often undermined by poor adherence to therapy. Not systematic differences in study design. This review evaluates the effect only is nonadherence the single greatest modifiable of study design on the comparative effectiveness of antipsychotic risk factor for relapse,2,3 it is also often undetected, formulations. The optimal use of different antipsychotic formulations resulting in lost opportunities to employ psychosocial in a general clinical setting depends on better understanding of the underlying reasons for differences in effectiveness across research interventions for adherence, as well as uncertainty as designs. to the relative contribution of lack of efficacy versus Data Sources: A PubMed literature review targeted English-language adherence problems to poor outcomes.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al
    US 201401.00249A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears et al. (43) Pub. Date: Apr. 10, 2014 (54) THERAPEUTIC TREATMENT A63/37 (2006.01) A613 L/45 (2006.01) (71) Applicants: Douglas Sears, Oak Park, CA (US); A613 L/4458 (2006.01) Michael Reilly, Oak Park, CA (US) (52) U.S. Cl. CPC ............... A61K 45/06 (2013.01); A61 K3I/451 (72) Inventors: Douglas Sears, Oak Park, CA (US); (2013.01): A613 L/4458 (2013.01); A61 K Michael Reilly, Oak Park, CA (US) 3 1/137 (2013.01); A61 K31/165 (2013.01) USPC .......................................................... S14/325 (21) Appl. No.: 14/046,528 (57) ABSTRACT (22) Filed: Oct. 4, 2013 This invention discloses a treatment for a patient receiving O O medication to treat an attention deficit disorder Such as Related U.S. Application Data ADHD wherein the treatment results in a loss of appetite and (60) Provisional application No. 61/744,948, filed on Oct. impairment of the patient's attentiveness. The treatment com 9, 2012, now abandoned. bines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases Publication Classification the caloric intake of a patient, which can increase the patients attentiveness. The combination treatment can be given for an (51) Int. Cl. indefinite, including, without limitation, life-long, to allow a A6 IK 45/06 (2006.01) patient to maintain normal caloric intake during treatment for A6 IK3I/65 (2006.01) an attention deficit disorder. 8aasaias: Patent Application Publication Apr. 10, 2014 Sheet 1 of 22 US 2014/010O249 A1 Figure i: improvement in Atiention with increased Caiotic intake 8aakast Patent Application Publication Apr.
    [Show full text]
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Treatment of Psychosis: 30 Years of Progress
    Journal of Clinical Pharmacy and Therapeutics (2006) 31, 523–534 REVIEW ARTICLE Treatment of psychosis: 30 years of progress I. R. De Oliveira* MD PhD andM.F.Juruena MD *Department of Neuropsychiatry, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil and Department of Psychological Medicine, Institute of Psychiatry, King’s College, University of London, London, UK phrenia. Thirty years ago, psychiatrists had few SUMMARY neuroleptics available to them. These were all Background: Thirty years ago, psychiatrists had compounds, today known as conventional anti- only a few choices of old neuroleptics available to psychotics, and all were liable to cause severe extra them, currently defined as conventional or typical pyramidal side-effects (EPS). Nowadays, new antipsychotics, as a result schizophrenics had to treatments are more ambitious, aiming not only to suffer the severe extra pyramidal side effects. improve psychotic symptoms, but also quality of Nowadays, new treatments are more ambitious, life and social reinsertion. We briefly but critically aiming not only to improve psychotic symptoms, outline the advances in diagnosis and treatment but also quality of life and social reinsertion. Our of schizophrenia, from the mid 1970s up to the objective is to briefly but critically review the present. advances in the treatment of schizophrenia with antipsychotics in the past 30 years. We conclude DIAGNOSIS OF SCHIZOPHRENIA that conventional antipsychotics still have a place when just the cost of treatment, a key factor in Up until the early 1970s, schizophrenia diagnoses poor regions, is considered. The atypical anti- remained debatable. The lack of uniform diagnostic psychotic drugs are a class of agents that have criteria led to relative rates of schizophrenia being become the most widely used to treat a variety of very different, for example, in New York and psychoses because of their superiority with London, as demonstrated in an important study regard to extra pyramidal symptoms.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Methylphenidate Versus Dexamphetamine in Children with Attention Deficit Hyperactivity Disorder: a Double-Blind, Crossover Trial
    Methylphenidate Versus Dexamphetamine in Children With Attention Deficit Hyperactivity Disorder: A Double-blind, Crossover Trial Daryl Efron, FRACP; Frederick Jarman, FRACP; and Melinda Barker, Grad Dip Ed Psych ABSTRACT. Objective. To compare methylphenidate behavioral, academic, and social functioning. Many (MPH) and dexamphetamine (DEX) in a sample of chil- well-designed, placebo-controlled studies have dem- dren with attention deficit hyperactivity disorder onstrated beyond doubt the benefits of stimulants in (ADHD). the vast majority of children with ADHD.2–4 In a Method. A total of 125 children with ADHD received review of 110 studies on the effects of stimulant both MPH (0.3 mg/kg twice daily) and DEX (0.15 mg/kg drugs on more than 4200 children with ADHD, twice daily) for 2 weeks a double-blind, crossover study. 4 ; Outcome measures were Conners’ Parent Rating Scale– Barkley found that 75% of subjects were regarded Revised, Conners’ Teacher Rating Scale–Revised, a Par- as improved on stimulants. The mean placebo re- ent Global Perceptions questionnaire, the Continuous sponse was 39%. Performance Test, and the Barkley Side Effects Rating Methylphenidate (MPH) and dexamphetamine Scale. (DEX) are the two stimulants prescribed most fre- Results. There were significant group mean im- quently and have been shown to have similar types provements from baseline score on all measures for of positive effects in children with ADHD. However, both stimulants. On the Conners’ Teacher Rating Scal- it is not known whether one is more efficacious than e–Revised, response was greater on MPH than DEX on the other in terms of probability of producing a the conduct problems and hyperactivity factors, as well positive response, magnitude of response, quality of as on the hyperactivity index.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Relief of Hypersensitivity After Nerve Injury from Systemic Donepezil
    Saranya devi Relief of Hypersensitivity after Nerve Injury from ALN Systemic Donepezil Involves Spinal Cholinergic and γ-Aminobutyric Acid Mechanisms Spinal ACh and GABA Mechanisms for Donepezil Analgesia Masafumi Kimura, M.D.,* Ken-ichiro Hayashida, D.V.M., Ph.D.,† James C. Eisenach, M.D.,‡ KIMURA ET AL. Shigeru Saito M.D.,§ Hideaki Obata, M.D.‖ XX ABSTRACT What We Already Know about This Topic • Donepezil increases central nervous system acetylcholine lev- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/118/1/173/259568/0000542-201301000-00030.pdf by guest on 28 September 2021 10.1097/ALN.0b013e318277a81c Background: Evoking spinal release of acetylcholine (ACh) els and is used for treatment of dementia produces antinociception in normal animals and reduces • Increases in spinal acetylcholine levels have been implicated in the relief of neuropathic pain hypersensitivity after nerve injury, and some studies suggest January that ACh-mediated analgesia relies on γ-aminobutyric acid (GABA)-ergic signaling in the spinal cord. In this study, the authors tested the spinal mechanisms underlying the anti- What This Article Tells Us That Is New 118 hypersensitivity effects of donepezil, a central nervous sys- • Donepezil increased spinal acetylcholine levels and γ- tem–penetrating cholinesterase inhibitor, in a rat model of aminobutyric acid levels to reduce nociceptive responses after nerve injury and represents a potential therapeutic pathway to neuropathic pain. reduce pain after nerve injury Methods: Male Sprague-Dawley rats were anesthetized, and L5 spinal nerve ligation was performed unilaterally. With- A antagonist; and CGP 35348 (30 μg), a γ-aminobutyric drawal threshold to a paw pressure test was measured before acid receptor type B antagonist.
    [Show full text]
  • Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the Use of Antiemetics Author(S): Dr Annette Edwards (Chai
    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the use of Antiemetics Author(s): Dr Annette Edwards (Chair) and Deborah Royle on behalf of the Yorkshire Palliative Medicine Clinical Guidelines Group Overall objective : To provide guidance on the evidence for the use of antiemetics in specialist palliative care. Search Strategy: Search strategy: Medline, Embase and Cinahl databases were searched using the words nausea, vomit$, emesis, antiemetic and drug name. Review Date: March 2008 Competing interests: None declared Disclaimer: These guidelines are the property of the Yorkshire Palliative Medicine Clinical Guidelines Group. They are intended to be used by qualified, specialist palliative care professionals as an information resource. They should be used in the clinical context of each individual patient’s needs. The clinical guidelines group takes no responsibility for any consequences of any actions taken as a result of using these guidelines. Contact Details: Dr Annette Edwards, Macmillan Consultant in Palliative Medicine, Department of Palliative Medicine, Pinderfields General Hospital, Aberford Road, Wakefield, WF1 4DG Tel: 01924 212290 E-mail: [email protected] 1 Introduction: Nausea and vomiting are common symptoms in patients with advanced cancer. A careful history, examination and appropriate investigations may help to infer the pathophysiological mechanism involved. Where possible and clinically appropriate aetiological factors should be corrected. Antiemetics are chosen based on the likely mechanism and the neurotransmitters involved in the emetic pathway. However, a recent systematic review has highlighted that evidence for the management of nausea and vomiting in advanced cancer is sparse. (Glare 2004) The following drug and non-drug treatments were reviewed to assess the strength of evidence for their use as antiemetics with particular emphasis on their use in the palliative care population.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]